Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell Lines
en-GBde-DEes-ESfr-FR

Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell Lines

29/04/2025 Compuscript Ltd
https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2025-0041
Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor. Cell and gene therapy, which offer many advantages in treating BLCA, are urgently needed. However, there is an important limitation of the currently reported single chain antibody used as a chimeric antigen receptor (CAR) targeting domain. Specifically, CAR aggregation leads to CAR-T depletion, which may originate from the linker peptide and folding stability between the variable domains (VH and VL) of the single chain antibody of the CAR. Humanized, small size, strong affinity single domain antibodies (variable domain of heavy chain of heavy-chain antibody [VHH]) derived from camelids are promising alternatives.
Second-generation Nectin4-targeted VHH-CAR-T cells were constructed and the specific killing efficacy was determined against BLCA cells in vitro. VHH Nectin4-CAR lentivirus was transduced into human T cells and CAR-T cell phenotypes were analyzed by flow cytometry. Cell killing efficacy was assessed using Nectin4-positive BLCA cells (SW780 and RT4) and Nectin4-negative U87-MG cells as controls using the xCELLigence Real Time Cell Analysis system. Cytokine secretion expression (IFN-γ and IL-2) were measured by an enzyme-linked immunosorbent assay.
VHHNectin4-CAR lentivirus treatment increased the proportion of CD4+ T and memory T cells. VHHNectin4-CAR-T cells had increased specific killing ability compared to the control using VH-VL-based CAR-T cells, specifically recognized Nectin4+ BLCA cells, secreted cytokines, and mediated cell apoptosis. Furthermore, VHHNectin4-CAR-T had no effect on Nectin4- U87-MG cell growth.
VHHNectin4-CAR-T cells were established with potent killing ability that specifically recognized Nectin4+ BLCA cells in vitro.
# # # # # #
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.

BIOI is now open for submissions; articles can be submitted online at:
https://mc04.manuscriptcentral.com/bioi

Please visit www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/

Please visit www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/

BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (www.bio-integration.org).

Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).
There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).

ISSN 2712-0074
eISSN 2712-0082

Jinping Niu, Guodi Liu and Sai Zhang et al. Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell Lines. BIOI. 2025. Vol. 6(1). DOI: 10.15212/bioi-2025-0041
# # # # # #
Jinping Niu, Guodi Liu and Sai Zhang et al. Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell Lines. BIOI. 2025. Vol. 6(1). DOI: 10.15212/bioi-2025-0041
29/04/2025 Compuscript Ltd
Regions: Europe, Ireland
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement